UBS analyst Cleve Rueckert downgrades Newmont (NYSE:NEM) from Buy to Neutral and lowers the price target from $59 to $53.
Citigroup Upgrades ResMed to Buy
Citigroup analyst John Deakin-Bell upgrades ResMed (NYSE:RMD) from Neutral to Buy.
UBS Downgrades Newmont to Neutral, Lowers Price Target to $53
UBS analyst Cleve Rueckert downgrades Newmont (NYSE:NEM) from Buy to Neutral and lowers the price target from $59 to $53.
Related Posts
Reported January 21, 2024 ‘SEC Probes B. Riley Deals With Client Tied To Failed Hedge Fund; Firm Says It Hasn’t Received Anything From SEC On The Matter; Nomura Arranged Partial Financing For Client’s FRG Buyout’ – Bloomberg News
https://www.bloomberg.com/news/articles/2024-01-22/sec-probes-b-riley-deals-with-client-tied-to-failed-hedge-fund US authorities are investigating B. Riley Financial Inc.'s deals with a key client who was linked to
The Latest Analyst Ratings for Nova
Over the past 3 months, 4 analysts have published their opinion on Nova (NASDAQ:NVMI) stock. These analysts are…
Recon Technology 1H 2023 EPS RMB$(0.88); Revenue RMB$45.6M
First Six Months of Fiscal 2023 Financial Metrics:
Total revenue decreased by approximately RMB8.8 million ($1.3 million) or 16.3% to RMB45.6 million ($6.6 million) for the six